Firstly, apologies for earlier referring to PCC investors as 'Tollhurst' clients, I meant to say Taylor Collison client.
Secondly, gs, when you mention you flicked through the Biogaia Feb report, were you referring to the 2006 report that was issued in Feb 2007? (i.e. This document- http://www.biogaia.com/public/documents/Interim_Report_ENG/070214eng.pdf) If so, their report definately makes for better reading than PCC's. It is a shame that PCC didn't get a small mention in the report, I'm still not sure which way Biogaia will go remembering that their investment to date in PCC is relatively minor (around $100k). As I have stated before, the pending decision by Biogaia as to their long-term strategy with PCC will be a company-maker in my opinion. To date, they are one of only a few commercial entities to actually review the PCC strain for its benefits, and will provide a fair indication of whether it is all worthwhile.
PCC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
